Archived Grant Opportunity View - GO1590

The 2018-19 Budget provided funding for ‘Improving Access to Medicines – Strengthening Quality Use of Healthcare Services’ to develop and deliver educational resources, tools and other interventions to support high quality healthcare outcomes and the sustainability of the Australian health system.

The Budget measure is being implemented through the Value in Prescribing (VIP) program with two open, competitive grant opportunities:

• immunoglobulin products stream (GO1590); and

• biological disease modifying anti-rheumatic drugs stream (bDMARDs) (GO1512), which is published separately at GrantConnect.

The objective of the VIP program’s immunoglobulin grant (GO1590) is to develop and deliver educational resources, tools, and awareness raising activities to support prescribers with the clinical use of immunoglobulin products funded under the national blood arrangements. Treatment plans developed in conjunction with patients should be in accordance with National Policy, the Immunoglobulin Governance Program, and the Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia. The grant opportunity is designed to complement the National Blood Authority's (NBAs) existing governance framework in continually improving quality in prescribing and best-practice clinical use of immunoglobulin.

The successful grant recipient will be required to engage key immunoglobulin product stakeholders throughout the project, including the NBA in accordance with its approved communication plan.  
At the conclusion of the grant activity, the grant recipient will be required to participate with the Department of Health in a complementary review of the effectiveness of the interventions designed and developed as part of this grant.

To be eligible you must be an organisation described in Section 3.1 in the Grant Opportunity Guidelines.

$2,400,000.00

From $2,400,000.00 to $2,400,000.00

 Submit your completed application to Grant.ATM@health.gov.au

An organisation may submit only one application, either as the applicant entity, or as a member of one consortia.